Skip to content

Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service

Research output: Contribution to journalReview article

Standard

Action on neovascular age-related macular degeneration (nAMD) : recommendations for management and service provision in the UK hospital eye service. / Gale, Richard P.; Mahmood, Sajjad; Devonport, Helen; Patel, Praveen J.; Ross, Adam H.; Walters, Gavin; Downey, Louise; El-Sherbiny, Samer; Freeman, Mary; Berry, Simon; Jain, Nitin.

In: Eye, Vol. 33, No. Suppl 1, 29.03.2019, p. 1-21.

Research output: Contribution to journalReview article

Harvard

Gale, RP, Mahmood, S, Devonport, H, Patel, PJ, Ross, AH, Walters, G, Downey, L, El-Sherbiny, S, Freeman, M, Berry, S & Jain, N 2019, 'Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service', Eye, vol. 33, no. Suppl 1, pp. 1-21. https://doi.org/10.1038/s41433-018-0300-3

APA

Gale, R. P., Mahmood, S., Devonport, H., Patel, P. J., Ross, A. H., Walters, G., ... Jain, N. (2019). Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service. Eye, 33(Suppl 1), 1-21. https://doi.org/10.1038/s41433-018-0300-3

Vancouver

Author

Gale, Richard P. ; Mahmood, Sajjad ; Devonport, Helen ; Patel, Praveen J. ; Ross, Adam H. ; Walters, Gavin ; Downey, Louise ; El-Sherbiny, Samer ; Freeman, Mary ; Berry, Simon ; Jain, Nitin. / Action on neovascular age-related macular degeneration (nAMD) : recommendations for management and service provision in the UK hospital eye service. In: Eye. 2019 ; Vol. 33, No. Suppl 1. pp. 1-21.

Bibtex

@article{2e4da98b017e430ca083234f7ef54b86,
title = "Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service",
abstract = "This report by a group of UK retina specialists and health professionals considers best practice recommendations for the management of sight-threatening neovascular age-related macular degeneration (nAMD), based on collective experience and expertise in routine clinical practice. The authors provide an update for ophthalmologists, allied healthcare professionals and commissioners on practice principles for optimal patient care and service provision standards. Refinement of care pathways for nAMD has improved access to intravitreal anti-vascular endothelial growth factor therapy but there are still variations in care and reported outcomes between clinic centres. Innovative organisational models of service provision allow providers to better match capacity with increasing demand. The authors review the recent NICE guideline for diagnosis and management of AMD, considerations for switching therapies and stopping treatment and need for regular monitoring of non-affected fellow eyes in patients with unilateral nAMD. Actions for delivery of high-quality care and to improve long-term patient outcomes are discussed. Local pathways need to detail nAMD target time to treat, maintenance of review intervals to ensure proactive treatment regimens are delivered on time and appropriate discharge for patients deemed low risk or no longer benefiting from treatment. Actual visual acuity outcomes achieved and maintenance of the level of vision when disease stability is achieved are considered good measures for judging the quality of care in the treatment of patients with nAMD. Robust community referral pathways must be in place for suspected reactivation of choroidal neovascularisation and rapid referral for second eye involvement. Practical considerations for intravitreal injection therapy are outlined.",
author = "Gale, {Richard P.} and Sajjad Mahmood and Helen Devonport and Patel, {Praveen J.} and Ross, {Adam H.} and Gavin Walters and Louise Downey and Samer El-Sherbiny and Mary Freeman and Simon Berry and Nitin Jain",
year = "2019",
month = "3",
day = "29",
doi = "10.1038/s41433-018-0300-3",
language = "English",
volume = "33",
pages = "1--21",
journal = "Eye",
issn = "0950-222X",
publisher = "Springer Nature",
number = "Suppl 1",

}

RIS - suitable for import to EndNote

TY - JOUR

T1 - Action on neovascular age-related macular degeneration (nAMD)

T2 - recommendations for management and service provision in the UK hospital eye service

AU - Gale, Richard P.

AU - Mahmood, Sajjad

AU - Devonport, Helen

AU - Patel, Praveen J.

AU - Ross, Adam H.

AU - Walters, Gavin

AU - Downey, Louise

AU - El-Sherbiny, Samer

AU - Freeman, Mary

AU - Berry, Simon

AU - Jain, Nitin

PY - 2019/3/29

Y1 - 2019/3/29

N2 - This report by a group of UK retina specialists and health professionals considers best practice recommendations for the management of sight-threatening neovascular age-related macular degeneration (nAMD), based on collective experience and expertise in routine clinical practice. The authors provide an update for ophthalmologists, allied healthcare professionals and commissioners on practice principles for optimal patient care and service provision standards. Refinement of care pathways for nAMD has improved access to intravitreal anti-vascular endothelial growth factor therapy but there are still variations in care and reported outcomes between clinic centres. Innovative organisational models of service provision allow providers to better match capacity with increasing demand. The authors review the recent NICE guideline for diagnosis and management of AMD, considerations for switching therapies and stopping treatment and need for regular monitoring of non-affected fellow eyes in patients with unilateral nAMD. Actions for delivery of high-quality care and to improve long-term patient outcomes are discussed. Local pathways need to detail nAMD target time to treat, maintenance of review intervals to ensure proactive treatment regimens are delivered on time and appropriate discharge for patients deemed low risk or no longer benefiting from treatment. Actual visual acuity outcomes achieved and maintenance of the level of vision when disease stability is achieved are considered good measures for judging the quality of care in the treatment of patients with nAMD. Robust community referral pathways must be in place for suspected reactivation of choroidal neovascularisation and rapid referral for second eye involvement. Practical considerations for intravitreal injection therapy are outlined.

AB - This report by a group of UK retina specialists and health professionals considers best practice recommendations for the management of sight-threatening neovascular age-related macular degeneration (nAMD), based on collective experience and expertise in routine clinical practice. The authors provide an update for ophthalmologists, allied healthcare professionals and commissioners on practice principles for optimal patient care and service provision standards. Refinement of care pathways for nAMD has improved access to intravitreal anti-vascular endothelial growth factor therapy but there are still variations in care and reported outcomes between clinic centres. Innovative organisational models of service provision allow providers to better match capacity with increasing demand. The authors review the recent NICE guideline for diagnosis and management of AMD, considerations for switching therapies and stopping treatment and need for regular monitoring of non-affected fellow eyes in patients with unilateral nAMD. Actions for delivery of high-quality care and to improve long-term patient outcomes are discussed. Local pathways need to detail nAMD target time to treat, maintenance of review intervals to ensure proactive treatment regimens are delivered on time and appropriate discharge for patients deemed low risk or no longer benefiting from treatment. Actual visual acuity outcomes achieved and maintenance of the level of vision when disease stability is achieved are considered good measures for judging the quality of care in the treatment of patients with nAMD. Robust community referral pathways must be in place for suspected reactivation of choroidal neovascularisation and rapid referral for second eye involvement. Practical considerations for intravitreal injection therapy are outlined.

UR - http://www.scopus.com/inward/record.url?scp=85063958134&partnerID=8YFLogxK

U2 - 10.1038/s41433-018-0300-3

DO - 10.1038/s41433-018-0300-3

M3 - Review article

C2 - 30926932

AN - SCOPUS:85063958134

VL - 33

SP - 1

EP - 21

JO - Eye

JF - Eye

SN - 0950-222X

IS - Suppl 1

ER -